字号·· | 护眼
南华早报

礼来抢先诺和诺德,口服GLP-1减重药在华获批Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

点「原文对照」整页切到原文,或双击某段只看那段的原文。

中国已批准美国制药巨头礼来公司的减重药丸奥福格列普汀,使其成为中国首个可用的口服GLP-1肥胖症治疗药物,全球药企正寻求进入中国庞大的体重管理市场。

China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market.

中国国家药品监督管理局周四宣布批准,称这种每日服用一次的药丸,商品名为Foundayo,可用于肥胖或超重成年人的慢性体重管理。

China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults.

GLP-1受体激动剂是GLP-1(即胰高血糖素样肽-1)的合成版本,这是一种天然存在的调节食欲和血糖的激素。近年来,它们已成为全球最畅销的药物之一。

GLP-1 receptor agonists are synthetic versions of GLP-1, or glucagon-like peptide-1, a naturally occurring hormone that regulates appetite and blood sugar. In recent years, they have become some of the world’s bestselling drugs.

礼来公司的药丸将与已在中国获得关注的GLP-1注射剂竞争,包括丹麦巨头诺和诺德的重磅药物司美格鲁肽(商品名Wegovy)、中国企业信达生物的马珠单抗,以及礼来自身的替尔泊肽。

Eli Lilly’s pill will compete with GLP-1 injections that have already gained traction in China, including Danish giant Novo Nordisk’s blockbuster semaglutide, sold as Wegovy, Chinese firm Innovent Biologics’ mazdutide, and Eli Lilly’s own tirzepatide.

在一项近期的临床研究中,服用最高剂量奥福格列普汀72周的患者平均减重12.4公斤,约40%的患者体重减轻超过15%。

In a recent clinical study, patients receiving the highest dose of orforglipron for 72 weeks achieved an average weight loss of 12.4kg, with about 40 per cent losing more than 15 per cent of their body weight.

礼来公司周四在声明中表示,该药丸为偏好注射剂替代方案的中国患者提供了新选择。诺和诺德申请在华销售口服版本的事宜尚待批准。

The pill offered a new option for Chinese patients who preferred an alternative to injections, Eli Lilly said in a statement on Thursday. Novo’s application to sell an oral version in China is pending approval.

中国一直在应对日益严峻的肥胖挑战,政府预测到2030年,65%的人口将超重。

China has been grappling with a growing obesity challenge, with government forecasts predicting that 65 per cent of the population would be overweight by 2030.

咨询公司L.E.K.去年在一份报告中称,中国GLP-1药物市场除治疗肥胖外还用于治疗糖尿病,预计到2030年将达到1000亿元人民币(约合150亿美元)。

The Chinese market for GLP-1 drugs, used to treat diabetes in addition to obesity, was expected to hit 100 billion yuan (US$15 billion) by 2030, consulting firm L.E.K. said in a report last year.

礼来公司已加大在华布局,中国是一个不断壮大的生物技术创新中心,也是全球第二大医疗健康市场。3月,礼来承诺在未来十年向中国投资30亿美元,以提升其本地供应链和制造能力。

Eli Lilly has ramped up its presence in China, a growing biotech innovation hub and the world’s second-largest healthcare market. In March, it pledged to invest US$3 billion in the country over the next decade to boost its local supply chain and manufacturing capabilities.

这家美国公司最近还在北京和上海设立了创新孵化器,以支持当地的生物技术初创企业。

The US company has also recently established innovation incubators in Beijing and Shanghai to support local biotech start-ups.

阅读媒体原文 ↗